1. Introduction

Artificial skin graft biotechnology is an emerging area of medical biotechnology involving the development, manufacture, testing, approval and transplantation of engineered skin products for the treatment of burns, chronic wounds, traumatic injuries and other skin defects.

Artificial skin grafts may include:

Bioengineered skin substitutes: Laboratory-produced materials designed to replace damaged skin.

Cultured epithelial autografts: Skin cells obtained from the patient, expanded in laboratories and transplanted back.

Allogeneic skin grafts: Skin cells or tissues obtained from another human donor.

Stem-cell-based skin grafts: Engineered skin products incorporating stem cells.

Bioprinted skin: Skin-like structures manufactured through three-dimensional bioprinting.

Synthetic skin substitutes: Artificial materials designed to support tissue regeneration.

In Morocco, the regulatory challenge is to ensure that these products meet appropriate standards of safety, quality, efficacy, manufacturing integrity and ethical medical practice.

The approval of artificial skin graft biotechnology must be examined through Morocco's pharmaceutical legislation, medical-device regulation, human-tissue governance, clinical-research requirements, public-health legislation and constitutional protections.

An important distinction is that Morocco does not necessarily have a single, dedicated statutory approval pathway specifically for every category of artificial skin graft. The applicable requirements depend on whether the product is classified as a medicine, medical device, human tissue or a combination product.

2. Main Legal Framework Governing Artificial Skin Grafts in Morocco

The following legislation provides the principal legal foundation.

These laws are listed in Morocco's Ministry of Health regulatory materials.

sante.gov.ma+2

3. Approval of Artificial Skin Graft Products under Law No. 17-04

Law No. 17-04, promulgated by Dahir No. 1-06-151 of 22 November 2006, establishes Morocco's Code of Medicines and Pharmacy.

It is relevant when an artificial skin graft is classified as a medicinal product or a biological product falling within the pharmaceutical regulatory framework.

Key regulatory requirements include:

Product identification and classification.

Quality and manufacturing documentation.

Evidence of safety and therapeutic efficacy.

Manufacturing-quality controls.

Appropriate regulatory authorization before marketing.

Post-marketing safety monitoring.

For cell-based artificial skin products, the manufacturer should establish the source, identity, viability, purity and biological characteristics of the cells.

A product containing living human cells may raise regulatory questions that do not arise with an ordinary synthetic wound dressing.

Legal issue: A manufacturer cannot assume that an engineered skin product is exempt from pharmaceutical authorization simply because it is applied externally rather than administered orally or intravenously.

The exact authorization pathway must be determined by the Moroccan health-product regulator, the Agence Marocaine du Médicament et des Produits de Santé (AMMPS), according to the product's characteristics.

sante.gov.ma+1

4. Regulation under Law No. 84-12 on Medical Devices

Law No. 84-12, promulgated by Dahir No. 1-13-90 of 30 August 2013, regulates medical devices in Morocco.

This legislation is particularly important for:

Artificial dermal matrices.

Synthetic skin substitutes.

Wound-covering biomaterials.

Regenerative scaffolds.

Skin-replacement devices.

Certain combination products.

The classification of the product depends on its intended medical purpose, design, composition and mode of action.

Important compliance requirements

A. Establishment declaration

Article 7 requires establishments involved in manufacturing, importing, exporting or distributing medical devices to make a prior declaration to the administration, accompanied by the prescribed documentation.

B. Product registration

The manufacturer or importer must follow the applicable device registration and regulatory requirements.

C. Quality assurance

The manufacturer should demonstrate appropriate controls over:

Raw materials.

Sterility and microbiological contamination.

Biocompatibility.

Mechanical performance.

Shelf life and storage.

Packaging and product traceability.

D. Post-market surveillance

Adverse reactions, contamination incidents, product failures and unexpected complications should be investigated and reported under the applicable regulatory requirements.

The Ministry of Health lists Law No. 84-12 and its implementing Decree No. 2-14-607 of 18 September 2014.

sante.gov.ma+1

5. Human Tissue Governance under Law No. 16-98

Law No. 16-98 is particularly significant when artificial skin grafts incorporate human-derived tissues or cells.

It was promulgated by Dahir No. 1-99-208 of 25 August 1999.

Article 2 defines human organs broadly to include human tissues, excluding tissues related to reproduction.

Article 3 provides that donation, procurement and transplantation must serve therapeutic or scientific purposes.

Article 4 establishes the requirement of prior donor consent, which is revocable.

Consequently, the legal position of different artificial skin products must be distinguished.

A critical issue is whether a laboratory-expanded skin graft remains within the scope of human-tissue transplantation legislation or also qualifies as a regulated medicinal product.

This requires a product-specific legal assessment rather than an automatic assumption that all artificial skin grafts are regulated identically.

Morocco's Ministry of Health also lists Decree No. 2-01-1643 of 9 October 2002 and Ministerial Order No. 2250-09 of 18 August 2009, which establishes good practices for the procurement, transplantation, preservation and transportation of human organs and tissues.

sante.gov.ma+1

6. Clinical Trials and Biomedical Research under Law No. 28-13

Law No. 28-13, promulgated on 4 August 2015, regulates the protection of persons participating in biomedical research.

It is relevant when a new artificial skin graft is being evaluated through clinical investigations involving human participants.

Examples include:

Testing the effectiveness of engineered skin in burn patients.

Evaluating stem-cell-based skin regeneration.

Comparing artificial grafts with conventional skin transplantation.

Studying wound healing and tissue rejection.

Investigating long-term graft safety.

Principal ethical and regulatory requirements

Research participants must receive appropriate information.

Informed consent must be obtained.

Research must be scientifically justified.

Risks must be assessed against anticipated benefits.

Participant safety must be protected.

Research must undergo the applicable ethics and regulatory review.

Adverse events must be appropriately managed and reported.

A manufacturer should not treat successful laboratory development as sufficient proof of clinical safety.

For example, a bioengineered skin product may demonstrate successful cell growth in laboratory conditions but still cause inflammation, infection, immune rejection or abnormal tissue development after transplantation.

sante.gov.ma+1

7. Data Protection and Genetic Information

Artificial skin biotechnology can involve highly sensitive personal information, particularly where products use patient-derived cells.

Law No. 09-08 governs personal-data processing in Morocco.

Relevant information may include:

Patient identity.

Medical history.

Genetic information.

Tissue-donor records.

Cell-culture records.

Clinical photographs.

Treatment outcomes.

Article 23 establishes security obligations for personal-data processing.

Article 22 addresses certain health-data processing activities and their declaration requirements.

Where genetic information or other specially protected information is processed, additional authorization requirements may apply.

Consequently, biotechnology companies should establish secure databases, restrict access to patient records and ensure lawful processing and transfer of personal data.

bdj.mmsp.gov.ma+1

8. Regulatory Authorities and Institutional Responsibilities

The principal institutions involved include:

The responsibilities of each institution depend on the product's legal classification and the activity being performed.

9. Important Moroccan Case Laws and Judicial Principles

There is an important limitation in the available jurisprudence: no directly reported Moroccan judgment specifically concerning the regulatory approval of a bioengineered artificial skin graft has been identified in the sources reviewed.

However, Moroccan decisions concerning medical-device registration provide relevant judicial principles.

Case 1: Casablanca Court of Appeal (Commercial), 13 December 2022

Medical devices: Registration certificate obligation rests with the importing-distributing entity rather than the foreign manufacturer.

Legislation: Law No. 84-12.

Legal issue: Who bears responsibility for obtaining the registration certificate necessary to commercialize medical devices in Morocco?

Decision: The Court of Appeal, following the point of law determined by the Court of Cassation, held that the registration obligation under Article 12 rested on the entity importing and distributing the products in Morocco, rather than the foreign manufacturer.

Legal principle: Regulatory compliance obligations must be allocated according to the applicable legislation and the distribution contract.

Application to artificial skin grafts: If a foreign biotechnology company supplies artificial skin graft products to a Moroccan importer, the parties must clearly allocate responsibility for obtaining the required Moroccan registration. The foreign manufacturer's technical documentation may be essential, but that does not automatically transfer the statutory registration obligation to it.

Jurisprudence+1

Case 2: Casablanca Court of Appeal (Commercial), 27 June 2019

Sale of medical devices: Failure to obtain the required registration certificate.

Legislation: Law No. 84-12, particularly Article 12.

Legal issue: Whether a supplier could demand payment when the medical devices could not legally be marketed because the necessary registration certificate had not been obtained.

Decision: The Court of Appeal held that the relevant registration obligation rested on the importing entity. The supplier's failure to satisfy that essential obligation undermined its claim for payment. The distributor's counterclaim for damages was rejected for insufficient proof.

Legal principle: Compliance with mandatory regulatory requirements is an essential consideration in commercial medical-device transactions.

Application to artificial skin grafts: A supplier cannot safely rely on a commercial contract alone to establish that an artificial skin graft is legally marketable in Morocco. The applicable registration and authorization requirements must be satisfied.

Jurisprudence+1

Case 3: Statutory judicial principle under Article 15 of Law No. 84-12

Although Article 15 is a statutory provision rather than a court judgment, it is particularly important for artificial skin graft approval.

It requires prior clinical investigation or, where justified equivalence exists, evaluation of clinical data from scientific literature.

The evidence must address:

Device performance under normal conditions of use.

Benefit-risk balance.

Adverse effects.

Compliance with essential safety and performance requirements.

Application: An artificial dermal matrix or other product classified as a medical device cannot rely solely on laboratory testing where the applicable regulatory framework requires clinical evidence.

Ma Loi

10. Clinical Safety and Product Liability

Artificial skin graft approval involves several potential liability situations.

A. Infection and contamination

If a graft causes infection because of inadequate manufacturing sterilization or cell-processing controls, the manufacturer, laboratory or other responsible party may face liability according to its fault and applicable legal duties.

B. Immune rejection

Where donor-derived skin cells cause unexpected immune reactions, investigators must examine whether the product was adequately characterized, tested and accompanied by appropriate warnings.

C. Manufacturing defects

A graft containing contaminated cells, defective biomaterials or incorrectly processed tissue may raise product-defect and professional-negligence issues.

D. Misleading commercial claims

A company must not advertise an experimental graft as an established cure or guarantee complete skin regeneration without adequate scientific support.

E. Medical negligence

Healthcare professionals must use appropriate clinical judgment, explain material risks, obtain valid consent and monitor the patient's condition.

These issues should be assessed under the applicable pharmaceutical, medical-device, civil-liability, professional and consumer-protection rules.

11. Importation and Cross-Border Distribution

Morocco may receive artificial skin graft products manufactured in Europe, the United States, Asia or other jurisdictions.

Importers must distinguish between:

Imported synthetic skin substitutes.

Imported donor-derived skin tissue.

Imported cell-based products.

Imported laboratory-produced tissue-engineering materials.

The applicable legal requirements differ.

For medical devices, Law No. 84-12 establishes the registration framework. Article 13 provides specified exceptions from ordinary registration, including certain experimental devices used for biomedical research, subject to the applicable legal requirements and specific administrative authorization.

For human tissues, Law No. 16-98 and its implementing provisions must also be considered. Article 28 specifically regulates the authorization of imports of human organs within its scope.

Ma Loi+2

12. Regulatory Challenges in Morocco

Several challenges arise when approving artificial skin graft biotechnology.

An additional recent development is Moroccan Decree No. 223 of 30 April 2026, published on 4 May 2026, which amends Decree No. 2-20-326 implementing Law No. 28-13 on biomedical research. Its provisions should be considered when evaluating the current clinical-research approval framework.

Eastlaws

13. Recommendations for Strengthening Artificial Skin Graft Regulation

Morocco could improve its artificial skin graft regulatory system through the following measures:

1. Dedicated biotechnology classification: Establish clearer classifications for engineered tissues, cellular products and synthetic skin substitutes.

2. Specialized approval procedures: Develop product-specific regulatory guidance for cultured skin, stem-cell-derived grafts and bioprinted tissues.

3. Clinical evidence requirements: Establish appropriate standards for clinical safety, graft survival, wound healing and long-term outcomes.

4. Manufacturing standards: Strengthen quality assurance for cell banks, tissue-processing facilities and biotechnology laboratories.

5. Donor protection: Improve donor consent, tissue traceability and safeguards against commercial exploitation.

6. Post-market monitoring: Establish effective reporting mechanisms for infection, graft rejection, treatment failure and other adverse events.

7. International regulatory cooperation: Encourage cooperation with the European Medicines Agency, World Health Organization and other international regulatory bodies.

14. Conclusion

The regulation of artificial skin graft biotechnology approval in Morocco involves the interaction of pharmaceutical legislation, medical-device regulation, human-tissue transplantation law, biomedical research protections and personal-data legislation.

The most important legal instruments are:

Law No. 17-04 on medicines and pharmacy.

Law No. 84-12 on medical devices.

Law No. 16-98 on human organ and tissue donation and transplantation.

Law No. 28-13 on biomedical research.

Law No. 09-08 on personal-data protection.

The Casablanca Court of Appeal decisions of 2019 and 2022 provide useful judicial guidance on medical-device registration responsibilities, although neither directly concerns artificial skin grafts.

The central legal principle is that artificial skin graft biotechnology must undergo the regulatory assessment appropriate to its actual composition, biological characteristics, intended purpose and method of manufacture before it can lawfully be commercialized or used in clinical practice.

15. Important Legal References and Research Sources

Moroccan Ministry of Health – Regulation applicable to health products.

Moroccan Ministry of Health – Human organ and tissue transplantation legislation.

Moroccan Ministry of Health – Biomedical research legislation.

Moroccan medical-device legislation and related case law.

Article 15 of Law No. 84-12 – Clinical evidence requirements.

Moroccan National Commission for Personal Data Protection (CNDP).

Academic research note: The distinction between directly applicable Moroccan legislation, Moroccan judicial decisions and comparative international jurisprudence is essential. The two Casablanca decisions discussed above are genuine Moroccan judicial authorities, but should not be cited as judgments specifically approving artificial skin graft biotechnology.